Search Orphan Drug Designations and Approvals
-
Generic Name: | fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha |
---|---|
Date Designated: | 03/09/2021 |
Orphan Designation: | Treatment of Mucosal Melanoma |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Mural Oncology, Inc. 852 Winter Street Waltham, Massachusetts 02451-1420 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-